Opens in a new tab or window An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction ...

At week 24 of the year-long study, 14% of patients with early-stage Alzheimer's who received a lower starting dose of the monthly infusion had the brain swelling side effect known as ARIA-E.

Eli Lilly & Co. said that a small change in dosing its Alzheimer’s drug Kisunla cut patients’ rate of brain-swelling side effects in preliminary results from a study. A more gradual increase ...